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ABSTRACT  
 
Extracellular vesicles (EVs), are naturally occurring cargo delivery tools with the potential to be used 
as drug vehicles of single agents or combination therapies. We previously demonstrated that human 
lung cancer cell-derived EVs could be used for the systemic delivery of oncolytic virus (OVs) and 
chemotherapy drugs such as paclitaxel (PTX), leading to enhanced anti-tumor effects in nude mice. 
In the current work, we evaluated the biodistribution of EVs by using bioluminescence and 
fluorescence imaging technologies, thus proving the ability of these EVs-formulations to specifically 
target the neoplasia, while leaving other body tissues unaffected. Moreover, in vivo imaging of NFκB 
activation in an immunocompetent reporter mouse model allowed to demonstrate the selective ability 
of EVs to induce tumor-associated inflammatory reactions, which are characterized by immunogenic 
cell death and CD3+/CD4+/CD8+ T-cell infiltration. While EVs have the potential to induce a 
systemic immune reaction by pro-inflammatory cytokines, our study provides compelling evidences 
of a localized inflammatory effect in the peritumoral area. Collectively, our findings strongly support 
the systemic administration of EVs formulations with OVs alone or in combination with 
chemotherapy agents as a novel strategy aimed at treating primary and metastatic cancers.  
 
Key words: extracellular vesicles, oncolytic adenoviruses, drug delivery, lung cancer, 
immunocompetent cancer mouse models, in vivo imaging. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION  
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Tumors are heterogeneous complexes of cells [1] able to grow in an uncontrolled way and to 
develop mechanisms for evading immune responses [2–4]. Indeed, the tumor itself can enhance the 
suppression of antitumor immunity [5] by expressing inhibitory ligands such as: programmed death-
ligands (PD-1, PD-L1, PD-L2), NKG2D, MICA/B), [6] suppressors of NK and T-cell activation [7] 
and accelerate the production of immunosuppressive CD4+ T cells [8]. Therapies aimed at activating 
the host immune response [9] have been proven useful as monotherapy or in combination with other 
anti-neoplastic agents [10–14], particularly when tumors acquire resistance to standard therapies and 
become metastatic [15,16]. Among the novel therapeutic strategies aiming at targeting the host 
immune response against the tumor, treatment with OVs is one of the most promising approach [17–
20] since it combines the cytolytic activity with the ability of the virus to activate the immune system 
[21,22]. OVs can exhibit natural tumor-selective tropism or be genetically modified for cancer cell-
restricted replication (adenovirus,  poliovirus, herpes simplex) [23]. Moreover, OVs are purposefully 
engineered to preferentially infect, replicate in and kill cancer cells instead of normal cells [24–29]. 
Clinical trials testing OVs treatments as monotherapy have provided encouraging results in terms of 
safety [30,31]: in most of these trials, the route of administration of choice was intratumoral (i.t.) and 
achieved proof-of-principles results with the demonstration of tumor lysis, immunogenic cell death 
and production of type-I IFN [32]. However, the efficacy has remained limited [33]. Since not all 
tumours can be treated i.t. and since OVs monotherapy may not be sufficient to eradicate cancer 
cells, novel strategies addressing the issue of efficacy and safety for the systemic delivery of OVs 
alone or in combination with other anti-cancer agents are in high demand. 
       Extracellular vesicles (EVs), are nano- to micron-sized lipid membrane-bound vesicles secreted 
into the extracellular environment transporting proteins, lipids and nucleic acids from cell to cell 
[34,35]. They are naturally occurring cargo delivery agents with the potential to be used as vehicles 
for drug delivery [36–38], in particular for the combined administration of OVs with chemotherapy 
agents [39]; in addition to endogenous uptake mechanisms, their lipid membrane may further 
improve the permeability of drugs into target cells [40,41].  It has been reported that EVs have 
intrinsic cell targeting properties: cell surface structures, such as tetraspanins and integrins, may 
direct the EV uptake towards specific cells and protect therapeutic agents from opsonization and 
recognition by phagocytes, leading to a longer half-life and reduced side-effects in healthy cells and 
tissues [42,43]. EVs have been shown to be safe in several clinical trials [44,45], while their 
effectiveness in cancer therapy may strongly depends on their ability of EVs to target the tumor 
tissue: however, despite intense research in the field, still little is known about their in vivo 
biodistribution [35,46–49].   
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Herein, by using a mouse cancer cell line grown in an immunocompetent syngeneic NFκB-
luc2 reporter mouse model and a fluorescent dye  to track EVs [35], we took advantage of in vivo and 
ex vivo imaging technologies to evaluate, at the same time, the biodistribution and the effects of EV-
formulations carrying OVs and/or paclitaxel (PTX) on the immune system. We found that EVs 
enhanced the systemic delivery of anticancer agents resulting in an improved tumor-selective 
delivery, peritumoral immune-response associated with the targeted delivery of the virus, enhanced 
immunogenicity and infiltration of CD4+ and CD8+ T-cells.  
 
MATERIALS AND METHODS 
 
Cell culture 
LL/2 mouse lung cancer cell line was purchased from the American Type Culture Collection (ATCC, 
USA). The cells were cultured at 37 °C and 5 % CO2 in Dulbecco’s modified eagle medium (DMEM, 
Lonza, Switzerland) supplemented with 10 % fetal bovine serum (FBS, Gibco Laboratories, USA), 1 
% of 100 u/mL penicillin/streptomycin (Gibco Laboratories) and 1% L-glutamine (Gibco 
Laboratories).  
 
Oncolytic virus  
The construction and characterization of  Ad5D24-CpG has been described previously [50] by 
recombining a CpG-rich shuttle plasmid (pTHSN-CpG1) with a plasmid containing the 24 
adenovirus backbone. Viral stocks were expanded in human lung cancer cell line A549 and purified 
on cesium chloride gradients. The viral particle concentration was determined b y OD260-reading and 
standard TCID50 (tissue culture infectious dose 50) assay was performed to determine infectious 
particle titer. Virus was characterized by PCR and restriction enzyme.  
 
Paclitaxel (PTX) solutions  
A 50 mM stock solution of Paclitaxel (PTX; Selleck Chemicals) was prepared by dissolving PTX 
into di-methyl sulfoxide (DMSO) (Sigma- Aldrich). 5 μM PTX-PBS solution was used for in vitro 
studies and 10 μM PTX-PBS solution for in vivo studies. 
 
Production of EVs, Lipophilic Dye loaded EVs and EVs formulations  
In order to produce EVs 2.6 x 106 LL/2 cells were plated into T-175 flask in medium supplemented 
with 5 % FBS. The FBS growth media was ultra-centrifuged overnight (110 000 x g at 4°C for 18 h, 
Optima LE-80K ultracentrifuge, rotor type 50.2, Beckman Coulter) to remove EVs present in the 
serum.  
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EVs were isolated from the conditioned medium using differential centrifugation steps. First the 
conditioned medium was centrifuged at 500 x g in 4°C for 10 minutes to pellet cells (Allegra X-15R 
Centrifuge, Beckman Coulter). Then, the supernatant was collected and ultra-centrifuged for 2 h at 
100 000 x g in 4°C, using Optima L-80 XP ultra-centrifuge (Beckman Coulter) with rotor SW32Ti 
(Beckman Coulter). The supernatant was aspirated and EV- containing pellets re-suspended in PBS 
(Lonza) 100 μL and stored at - 80 °C.  
PTX-loaded EVs were prepared as previously described [37,39] by incubating 1 × 108–5 × 109 EVs 
in 1 mL of 5 μM PTX-PBS solution for in vitro samples and 10 μM PTX-PBS solution for in vivo 
samples, for 1 h at 22 °C. Then, the samples were centrifuged at 170000 ×g for 2 h to pellet the EVs. 
The supernatant containing unbound PTX was removed, and the EV-pellet was washed, suspended it 
in DPBS and pelletted it again at 170000 ×g.  
EVs were loaded with DiD lipohilic dye (EV-DiD) and prepared by incubating 1x108-5 x109 EVs for 
1 hour at RT with 5 μL of DiD (Biotium) per mL of EV suspension in PBS. Next, the samples were 
centrifuged at 150 000 x g for 3 h to pellet the EVs. The supernatant containing unbound DiD was 
removed, and the EV-pellet was washed by suspending it in PBS and pelleting it again at 150 000 x 
g. 
 
Production of EV-Virus formulations 
EV-encapsulated virus (EV-Virus) were produced as previously described [39], 2.6 x 106 of LL/2 
cells were infected with 10 viral particles/cell of Ad5D24CpG and were cultured at 37 °C and 5 % 
CO2 ..  48 h later when most of the cells were detached from the culture flask, the culture media were 
collected for EV-Virus isolation using differential centrifugation. First the conditioned medium was 
centrifuged at 500 x g and 4°C for 10 minutes, to separate the cells (Allegra X-15R Centrifuge, 
Beckman Coulter). Then, the supernatant containing EV-Virus was collected and ultra-centrifuged 
for 2 h at 100 000 x g and 4°C, using Optima L-80 XP ultra-centrifuge (Beckman Coulter) with rotor 
SW32Ti (Beckman Coulter). The supernatant was aspirated and pellets containing EV-Virus re-
suspended in PBS 100μL and stored at - 80 °C.  EV-Virus samples were incubated in 100 mM NaOH 
at room temperature for 20 minutes in order to inactivate any free not EV encapsulated virus present.  
Free virus used as controls was always inactivated for each experiment performed as previously 
reported [51,52]. Samples were subsequently neutralized by the addition of HCl 0.1 M.  
To generate EV-DiD-Virus, the EV-Virus formulation was incubated for 1h at RT in 5 μL of DiD per 
mL of EV suspension in DPBS. Samples were then centrifuged at 150 000 x g for 3 h at RT, in order 
to pellet EV-DiD-Virus. The washing procedure was repeated using PBS as diluent. The final EV-
DiD-Virus pellet was re-suspended in 100 μL of PBS and stored at -80 °C until use. 
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 Size distribution analysis by nanoparticle tracking analysis (NTA)  
Size distribution and concentration of EV, EV-PTX, EV-Virus and EV-Virus-PTX formulations were 
analyzed by NTA using Nanosight model LM14 (Nanosight) equipped with blue (404 nm, 70 mV) 
laser and sCMOS camera. The samples containing virus were incubated at +95 °C for 10 minutes in 
order to inactivate the viruses. NTA was performed for each sample by recording three 90 seconds 
videos, subsequently analyzed using NTA software 3.0 (Nanosight). The detection threshold was set 
to level 5 and camera level to 15. 
 
Zeta potential analysis by electrophoretic light scattering  
The zeta potential was measured using ZetaSizer Nano (Malvern, UK). All the samples were diluted 
in a volume of 800 μL of MilliQ H2O and injected with a 1 mL syringe in the capillary flow 
(DTS1070 folded capillary cell) for the measurement. An equilibration time of 120 seconds was set 
on the software to allow the samples to stabilize at 25°C inside the measurement chamber. Three 
parallel measurements were performed on each sample. 
 
Cryo-EM 
Cryo-EM images were acquired with a FEI Talos Arctica 200 kV FEG electron microscope equipped 
with a FEI Falcon 3EC direct electron detector and Volta Phase-plate. Prior to Cryo-EV imaging, 
samples were vitrified on a FEI Vitrobot IV apparatus, and processed as previously reported [53]. 
 
MTS cell viability assay  
LL/2 cells were seeded at a density of 1x104 cells/well in 96-well plates and maintained under 
standard growth condition. On the following day cells were treated in triplicates with control EVs (10 
particles/cell), Virus (10vp/cell), PTX (0.1 pmol/cell), Virus and PTX separately (Virus+PTX) (10 
vp/cell, 0.1 pmol/cell of PTX), EV-PTX (10 particles/cell, 0.1 pmol/cell of PTX), EV-Virus (10 
particles/cell), EV-Virus-PTX (10 particles/cell, 0.1 pmol/cell of PTX). Cell viability was determined 
by MTS assay according to the manufacturer's protocol (Cell Titer 96 AQueous One Solution Cell 
Proliferation Assay; Promega, Nacka, Sweden). The absorbance was measured with a 96-wells plate 
spectrophotometer Varioskan Flash Multimode Reader (Thermo Scientific) at 490 nm. The 
experiments were independently performed three times with triplicates of each condition in each 
experiment 
 
Immunogenicity of tumor cell death in vitro 
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Calreticulin (CRT) exposure. Cells were seeded in duplicate onto 6 well plates at 5x105 cells/well. 
Cells were treated with control EVs (10 particles/cell), Virus (10 vp/cell), Virus and PTX separately 
(Virus+PTX) (10 vp/cell, 0.1 pmol/cell of PTX), EV-PTX (10 particles/cell, 0.1 pmol/cell of PTX), 
EV-Virus (10 particles/cell), EV-Virus-PTX (10 particles/cell, 0.1 pmol/cell of PTX). After 24 h cells 
were harvested and stained with 1:1000 diluted rabbit polyclonal anti-Calreticulin antibody (Abcam, 
Cambridge, UK) for 40 minutes at 4°C subsequently with 1:100 diluted Alexa-Fluor 488 secondary 
antibody (Invitrogen, Carlsbad, CA) and analyzed by flow cytometry (LSR II, BD, Franklin Lakes, 
NJ). 
ATP release. Cell lines were seeded in triplicates onto 96 well plates at 1x104 cells/well and treated 
as mentioned above. Supernatants were collected after 48 h and analyzed with ATP Determination 
Kit according to manufacturer’s protocol (Promega, Madison, WI) for luminometric analysis 
(Varioscan Flash, ThermoFisher Scientific, Waltham, MA). 
 
In vivo biodistribution study 
Day 0 
Day of treatment 
Day 1 
Detection of intensity 
of photon emission 
(BLI) 
Day 1 
Detection of intensity 
of photon emission 
(Fluorescence) 
Vehicle X  
Virus 
(1x10
8
 vp/tumor) 
X - 
EV  
(1x10
9 
particles/tumor, and 5 
μL of DiD per mL of EV 
suspension) 
X - 
PTX 
(40µmol of PTX/kg) 
X - 
EV-PTX 
(1x10
8
 particles/tumor 
including 1x10
8
 vp/tumor, 
and 10 µM of PTX/kg) 
X - 
EV-Virus 
(1x10
8
 particles/tumor + 
1x10
8
 vp/tumor) 
X EV-DiD-Virus: 
1x10
8
 particles/tumor + 
0.5 μL of DiD/ tumor + 
1x10
8
 vp/tumor 
EV-Virus-PTX 
(1x10
8
 particles/tumor 
including 1x10
8
 vp/tumor 
and 40µmol of PTX/kg) 
X - 
Table 1. Study design for the in vivo biodistribution 
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All the animal experiments were performed and approved by the Italian Ministry of Research and 
University permission numbers: 12-12-30012012, 547/2015 and controlled by a Departmental panel 
of experts. The transgenic reporter NFκB-luc2 mouse was generated and characterized by our group  
and used for the in vivo studies [54].  The acclimatization period was 14 days prior to LL/2 cancer 
cell injections. Health status of the mice was monitored daily and as soon as signs of pain or distress 
were evident they were euthanized. For the bioluminescence study where the bioluminescent signal 
was related with the inflammation state of tissues, murine xenografts were established by injecting 
1x106 LL/2 cells s.c. into the neck of 12-week old male mice. The treatment groups were as follows:  
vehicle (n=5) (100 μL of PBS), EVs (n=5) (1x109particles/tumor), PTX (n=3) (40 µmol of PTX/kg), 
EV-Virus (n=5) (1x108 vp/tumor), EV-PTX (n=5) (1x108 particles/tumor and 40 µmol of PTX/kg), 
EV-Virus-PTX (n=5) (1x108 vp/tumor and 40 µmol of PTX/kg) (Table 1). The aim of the 
fluorescence study was to have a direct evidence of the specific tropism of EVs encapsulated with 
oncolytic viruses to the tumor, thus the fluorescent emission of a lipophilic dye (DiD) was related to 
the particle biodistribution. Therefore, we performed the following treatments: DiD (5 μL per mL of 
EV suspension in DPBS), EV-DiD-Virus (n=5) (1x108 particles/tumor + 1x108 vp/tumor). For the 
bioluminescence and fluorescent studies, treatment groups were administered i.v (100 µl) to mice 
with tumors (one tumor per mouse about 5 mm in diameter). Brain, tumors, livers and serum from 
NFκB-luc2 mouse were collected for quantitative real time PCR (LighCycler 480, Roche, Basel, 
Switzerland). 
 
In vivo and ex vivo imaging 
The in vivo bioluminescence imaging analysis was carried out at different time points, starting the 
day before injection of tumor cells, and ending 24 h post EV treatments (i.v.). For the 
bioluminescence imaging, animals were injected i.p. with 80 mg/kg of luciferin (Beetle Luciferin 
Potassium Salt; Promega, Madison, WI, USA) 15 minutes prior the imaging session. Then mice were 
anaesthetized using Isofluorane (Isofluorane-Vet; Merial, Lyon, France) and kept under anesthesia 
during imaging sessions carried out with the Imaging System (5 minutes for dorsal view and 5 
minutes for ventral view) (IVIS Lumina II Quantitative Fluorescent and Bioluminescent Imaging; 
PerkinElmer, Waltham, MA, USA). Photon emission in selected body areas was measured using the 
Living Image Software 3.2 (PerkinElmer). For the ex vivo imaging mice were treated with luciferin 
15 minutes prior euthanasia by cervical dislocation and ex vivo imaging of the selected organs was 
carried out immediately after death.  Bioluminescence from tissue explants was acquired over a 5 
minutes exposure time and quantified with the Living Image Software 3.2 (PerkinElmer).  
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The in vivo fluorescence imaging was carried out 24 h post i.v. EV treatments using the same 
Imaging System (IVIS Lumina II) with suitable filters (Cy5.5) and following the manufacturer 
instructions for fluorescence background subtraction. Similarly, to the above-described procedure for 
bioluminescence imaging, the ex vivo imaging acquisition of fluorescence was performed on tissue 
explants over an exposition time of 1 second. The quantification was done with Living Image 
Software 3.2 (PerkinElmer). 
 
 
Quantitative real-time PCR 
qPCR for adenovirus E4 copy number was carried out according to the protocol previously described 
[55] primer FW: 5’-GGA GTG CGC CGA GAC AAC-3’, primer RV: 5’-ACT ACG TCC GGC GTT 
CCA T-3’, probe E4: 5’-(6FAM)-TGG CAT GAC ACT ACG ACC AAC ACG ATC T- (TAMRA)-
3’[17]. Total DNA was extracted from LL/2 cells 48h post treatment in vitro and from resected 
brains, tumors, livers, blood from NFκB-luc2 mouse model after 24h post treatment, using the 
QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) according to manufacturer’s protocol. 
Subsequently isolated DNA was analyzed for adenoviral E4 copy number normalized to murine beta-
actin (liver, blood) ((primer FW: 5’-CGA GCG GTT CCG ATG C-3’, primer RV: 5’-TGG ATG 
CCA CAG GAT TCC AT-3’, probe murine beta-actin: 5’-(6FAM)-AGG CTC TTT TCC AGC CTT 
CCT TCT TGG-(TAMRA)-3’. Samples were analyzed using LighCycler qPCR machine (LighCycler 
480, Roche, Basel, Switzerland). 
 
Immune cell infiltration analysis 
Immune cell infiltration of tumors was analyzed using the flow cytometer BD LSR II (BD 
Biosciences) and FlowJo software (Tree Star, Ashland, OR, USA) at sacrifice (24h post-treatment). 
Specific lymphocites were quantified using antibodies CD45+ (Abcam, ab210185), CD3+ (Abcam, 
ab34275), CD4+ (Abcam, ab210348), CD8+ (Abcam, 25499). Tumors were harvested and weighted. 
Neoplastic tissues were dissociated with tumor dissociation kit mouse (Miltenyi Biotec 130-096-
730). After dissociation, cells were washed and stained with antibodies according to manufacturer’s 
instructions.  
 
 
Statistical analysis 
Statistical significance was analyzed by using one-way ANOVA with Tukey’s Multiple Comparison 
test and nonparametric Mann–Whitney test. All statistical analysis, calculations and tests were 
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performed using GraphPad Prism 5 (GraphPad Software, San Diego, CA).  
 
 
RESULTS 
Production of LL/2-derived EVs formulations and their ability to induce immunogenic cell 
death 
We previously demonstrated that human lung cancer cell-derived EVs could be useful vehicles for 
the systemic drug delivery of OVs and paclitaxel (PTX) to target and reduce tumor growth in nude 
mice with compromised immune system [39]. Since, OVs are able to trigger the host anti-tumor 
immunity actively contributing to their mechanism of action [56,57], in the current study, we aimed 
at evaluating the effects of EV formulations on the immune system; for testing these effects, we used 
a mouse lung cancer cell line (LL/2) to produce the EV-formulations (encapsulating PTX and OVs) 
and to generate a tumor model in immunocompetent syngeneic mice (C57Bl/6).  In a first set of 
experiments, we assessed whether the encapsulation of PTX and OVs into the LL/2-derived EVs had 
influence on the particle size distribution by using NTA (Figure 1AB). After encapsulation, free 
viruses remaining in solution were chemically inactivated as previously reported [51,52] and should 
not have played a significant role in the experiments carried out with the EV-Virus formulations. Size 
distribution of both control EVs and EV-Virus formulations were detected to be in the range of 50-
400 nm. The size distribution of EV-Virus overlapped with the size of the Virus with most of the EVs 
being smaller or the same size as the virus (Figure 1A). Additionally, no significant size differences 
were detected by adding PTX in EV-Virus-PTX and EV-PTX (EVs loaded with PTX) (Figure 1B). 
Indeed, EVs and EV-Virus had a negative zeta-potential of approximately -40 mV, while the free 
virus had a zeta-potential of -20 mV (Figure 1C). The zeta-potential was also comparable in EV-
Virus-PTX and EV-PTX formulations, as PTX is a chargeless molecule (Figure 1C). Cryo-EM 
experiments showed that virus was incorporated inside the vesicles. The adenovirus virion has a viral 
structure of 90–100 nm in size packed inside the EV (Figure 1D). Although we rigorously 
standardized the procedure for the encapsulation of the virus into the EVs, the ratio between free and 
EV-encapsulated virus could not be systematically determined.  The Cryo-EM images demonstrated 
that the free virus was less frequent compared to the encapsulated virus, but this was only a 
qualitative observation that for future clinical applications should be firmly determined. Nevertheless, 
the remaining free virus was routinely inactivated (please, see the procedure in the Material and 
Methods section) in the EV-Virus formulations before proceeding with the in vivo experiments. 
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Figure 1. Size and net-charge of murine lung cancer derived extracellular vesicles. (A-B) Size distribution of EVs, 
EV-Virus,Virus, Virus+PTX, EV-PTX and EV-Virus-PTX samples were determined by using Nano tracking analysis 
(NTA). (C) The surface charge of the EVs, Virus, EV-PTX, Virus+PTX, EV-Virus and EV-Virus-PTX was measured 
using ZetaSizer Nano Malvern. (D) Cryo-EM image of EVs, Virus and EV-Virus (scale bar 100 nm) was acquired with a 
FEI Talos Arctica 200 kV FEG electron microscope equipped with a FEI Falcon 3EC direct electron detector and Volta 
Phase-plate.  
 
These experiments confirmed that the encapsulation of PTX or OVs had only minimal effects on size 
and charge of the murine EVs, similarly to what have been observed with formulations obtained with 
human lung cancer EVs [39]. To gain insights into the anti-tumor activity of the LL/2-derived EVs 
formulations, we tested their cytotoxic effects on LL/2 cells with the MTS cell viability assay. In 
keeping with what we have previously reported [39], EV-Virus and EV-Virus-PTX showed enhanced 
anti-cancer activity when compared to cells treated with the Virus or PTX alone (Figure 2A) 
(p<0,001). To evaluate whether a program of immunogenic cell death was triggered by the 
treatments, the expression of specific markers, such as the exposure of calreticulin on cell surface and 
the extracellular release of ATP [58] were measured on murine lung cancer cells treated with EVs 
(10 particles/cell), Virus (10 vp/cell), PTX (0.1 pmol/cell), Virus and PTX separately (Virus+PTX) 
(10 vp/cell, 0.1 pmol/cell),), EV-PTX (10 particles/cell, 0.1 pmol/cell), EV-Virus (10 particles/cell), 
EV-Virus-PTX (10 particles/cell, 0.1 pmol/cell),), PTX (0.1 pmol/cell). The highest immunogenic 
cell death on tumor cells was observed with Virus+PTX and EV-Virus-PTX treatments (Fig. 2BC), 
while the EVs administration seemed not influencing either the immunogenic cell death or the viral 
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replication (Fig. 2D); the treatment with PTX slightly decreased viral replication although to a 
minimal extent (25%). These data suggested that all EV formulations, but not EVs alone, were able 
to counteract the growth of tumor cells and induce immunogenic cell death.      
Figure 2. Antitumor properties of extracellular vesicles as drug delivery vehicles. (A) Antineoplastic efficacy was 
measured by MTS cell viability assay in the LL/2 cell line. Cell viability was determined in untreated cells (control) and  
72 h post-treatment. (B) Extracellular ATP was measured from the different supernatants (LL/2 cells) 48h post-treatment 
using ATP determination kit. (C) Calreticulin exposure on outer cell surface of the murine lung cancer cells was 
measured 24h post-treatment by flow cytometer. (D) Adenoviral copies towards E4 gene were measured by qPCR from 
LL/2 cells 24h post-treatment. Error bars mean+/- SD *p<0.05, **p<0.01, ***p<0.001. 
 
Oncolytic viruses encapsulated in EVs induce inflammatory response only in the peritumoral 
area  
The ability of LL/2-derived EV formulations to induce immunogenic cell death in vitro, prompted us 
to verify whether their biodistribution and immunogenic effects were selective for the tumoral tissue 
in vivo.  To this aim, we used the NFκB-luc2 reporter mouse model in which it is possible to monitor 
in the spatio-temporal dimension the activation of the inflammatory pathway in the tissues of living 
systems [54]. The NFκB-luc2 model is a mouse genetically engineered with a firefly luciferase 
reporter gene (luc2), whose expression is under the control of an NFκB responsive promoter; in all 
the reporter mouse tissues (including blood cells),  upon activation of the NFκB transcription factor 
(the master regulator of inflammatory pathways), it is possible to identify the site of inflammation in 
vivo or ex vivo by bioluminescence imaging of the luciferase accumulation [54]. The NFκB-luc2 
reporter mouse was transferred into the C57Bl/6 background for the syngeneic engraftment of LL/2 
tumor cells. 1x106 LL/2 cells were s.c. injected in the periscapular dorsal area in six groups of five 
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NFκB-Luc2 reporter mice/group to evaluate the inflammatory reaction triggered by the different EV 
formulations (Figure 3). To this aim, in vivo bioluminescence imaging acquisitions were carried out 
following tumor growth from day -12 (injection of cancer cells) until the tumor reached the 
dimension of 5 mm, when mice were i.v. treated with the different formulations for 24h (Figure 3 and 
Table 1); treatments included: vehicle (PBS), Virus, PTX, EV, EV-PTX, EV-Virus and EV-Virus-
PTX. Photon emissions were acquired and quantified from the dorsal and ventral sides, to record any 
increase/decrease of luminescence before and after treatments. The emission from the dorsal area is 
generally mainly influenced by the tumor area, while from the ventral side, luminescence arises 
mainly from inner organs (lung, liver, spleen, intestine etc.). The photon emission significantly 
increased in the tumor area especially in mice treated with Virus, EV-Virus, EV- Virus-PTX (Figure 
3 CDE) as compared to the vehicle-treated mice (Figure 3A), while it was only slightly increased in 
mice treated with EV and EV- PTX (Figure 3BF). These results suggested that the treatments with 
Virus alone, EV-Virus, EV-Virus-PTX induced an enhanced NFkB dependent inflammatory 
response only in the peritumoral area (Figure 3AF). From the ventral side, bioluminescence only 
slightly increased in abdominal (Supplementary Figure 1), hepatic (Supplementary Figure 2) and 
chest (Supplementary Figure 3) areas following the lung tumor growth and was not dependent from 
the administered treatment, with the exception of PTX where a systemic inflammatory reaction was 
observed (Supplementary Figure 4). From these data, we concluded that systemic treatments with 
Virus, EV-Virus, EV-Virus-PTX selectively induced a tumor-associated inflammation, in line with 
the tumor-specificity of the virus, suggesting that EVs not only protect viral particles from the host 
immune system [59,60], but does not trigger per se any systemic inflammatory reaction.   
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Figure 3. EV-formulations induces tumor associated inflammation in NFKB-luc2 mice. (A-F) Quantification of the 
photon emission in the tumor areas at the indicated time points. At day 0 mice were treated with the indicated 
formulations. The tumor cells were injected at day -12. Data are expressed as BLI, average radiance (p/s/cm
2
/sr), mean ± 
SEM (N=5).  
 
 
Supplementary Figure 1. Tumor growth induces a generalized inflammatory reaction in the abdominal area.  (A-
F) Quantification of the photon emission in abdominal area at indicated time point. At day 0 mice were treated with the 
indicated formulations. Tumor cells were injected at day -12. Data are expressed as BLI, average radiance (p/s/cm
2
/sr), 
mean ± SEM (N=5).   
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Supplementary Figure 2. Tumor growth induces a generalized inflammatory reaction in hepatic area. (A-F) 
Quantification of the photon emission in hepatic area at indicated time point. At day 0 mice were treated with the 
indicated formulations. The tumor cells were injected at day -12. Data are expressed as BLI, average radiance 
(p/s/cm
2
/sr), mean ± SEM (N=5).   
 
 
Supplementary Figure 3. Tumor growth induces a generalized inflammatory reaction in chest. (A-F) Quantification 
of the photon emission in cheast area at indicated time point. At day 0 mice were treated with the indicated formulations. 
The tumor cells were injected at day -12. Data are expressed as BLI, average radiance (p/s/cm
2
/sr), mean ± SEM (N=5).  
 
 
Supplementary Figure 4. Systemic inflammation induced by treatment with paclitaxel . Paclitaxel treatment of 
NFKB-luc2 mice induces systemic activation of the NFkB-mediated transcription. (A-D) Quantification of the photon 
emission in the abdominal, hepatic and chest areas at the indicated time point. Day 0 is the day of paclitaxel 
administration (i.v.). Data are expressed as BLI, average radiance (p/s/cm
2
/sr), mean ± SEM (N=3).  
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To confirm that the BLI photon emission observed in vivo was due to the induction of a tumor-
associated inflammation and not from other body areas, mice were sacrificed 24 h after treatment and 
photon emission was measured ex vivo in specific organs. The 24h time point was chosen since 
preliminary time course experiments demonstrated that PTX and EV-PTX formulations were 
inducing NFkB transcription as early as 6 h after treatment (Supplementary Figure 5); thus 24 h was 
considered a sufficient time length to measure any residual PTX activity eventually distributing to 
organs other than the tumor. The intensity of photon emission showed that treatments with Virus 
alone, EV, EV-PTX, EV-Virus, EV-Virus-PTX were associated with inflammation at the tumor site 
(Figure 4ACDFGH) and not in any other organ; indeed, vehicle alone did not increase 
bioluminescence in the tumor at this stage of cancer growth (Figure 4 AB). Interestingly, PTX alone 
induced a systemic inflammation detectable in all organs tested that was clearly prevented by the EV 
encapsulation, indicating that EVs are indeed able to prevent the drug delivery to any other organs 
but the tumor (Figure 4AE).  
 
Supplementary Figure 5. In vivo bioluminescence of PTX and EV-PTX after 6h post-treatment. PTX and EV-PTX 
treatments show the induction of NFkB transcription 6 h after treatment 
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Figure 4.  Ex vivo bioluminescence is related to the induction of tumor associated inflammation. (A) Representative 
images that indicate the intensity of photon emission in organs explanted from NFKB-luc2. (B-H) Quantification of the 
photon emission from 7 indicated organs (brain, liver, spleen, kidneys, lung, intestine, tumor) dissected from NFKB-luc2 
mice 24h after i.v treatments. Data are expressed as BLI, average radiance (p/s/cm
2
/sr), mean ± SEM (N=5).  
 
 
Fluorescent labeling of EVs show a targeted delivery to the tumor site following systemic 
administration 
 
The ability of EV encapsulation to prevent the systemic inflammation induced by PTX administered 
alone, clearly suggested that EVs might have a specific tropism for the tumor compared to other body 
districts. In order to have a direct evidence of this specific targeting, we added to the formulation of 
EV-Virus (EV-DID-Virus) the fluorescent dye DiIC18(5); 1,1′-dioctadecyl-3,3,3′,3′- 
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tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate salt (DID) that is often used for in vivo 
applications for its high tissue penetrance and low interference with tissue autofluorescence 
[35,48,61]; then, we evaluated the biodistribution of the fluorescence after i.v. treatment with 1x108 
particles/tumor of EV-DID-Virus. The in vivo imaging acquisitions of fluorescence and 
bioluminescence were carried out 24h post-treatment (Figure 5A). The fluorescence imaging showed 
a specific signal arising from the tumor, thus providing a direct demonstration of the homing of the 
EV-DID-Virus particles to the neoplastic tissue. This cancer-specific targeting induced, the 
development of a peritumoral immune-response within 24 h (Figure 4B), which was visible in the 
reporter animals as a bioluminescent emission surrounding the tumor mass (Figure 5A). The 
immune-response was specifically associated with the targeted delivery of the Virus to the tumor site, 
since the bioluminescence signal was not observed in the mice treated with EVs alone (Figure 4B). 
The ex vivo imaging analysis of the fluorescence emission from the dissected organs showed a 
positive signal mostly within the tumor and the liver (Figure 5B).  This high ex vivo fluorescence in 
the liver is possibly due to the accumulation of free DiD released by the EVs following the injection,  
while the i.v. administration of the dye produced a preferential accumulation of the fluorescence in 
this organ (Supplementary Figure 6). In agreement with this conclusion, the quantification of the 
viral load by RT-PCR did not provide evidence of the presence of viral particles in the liver, where 
we found levels comparable with those measured in samples used as negative controls, such as t he 
brain and serum; in contrast, as expected, a very high titer was detected in the tumor (Figure 6A). By 
changing the scale of fluorescence of three orders of magnitude, minor distribution could be detected 
also in other tissues mainly spleen, brain, kidneys, lungs and intestine, although these signals were 
lower than those detected in the tumor (Supplementary Figure 7). The higher signal in spleen (among 
the lowers) is in agreement with previous reports with other nanoparticles showing a preferential 
uptake in the spleen; this phenomena might be less evident in our experiments because of the tumor 
tropism of EVs. 
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Figure 5.  Extracellular vesicles loaded with oncolytic viruses show positive fluorescent signal at the tumor site. (A) 
Representative images of the photon emission (BLI and fluorescence) in the tumor area of tumor-bearing NFKB-luc2 
mice that were intravenously injected with EV-DiD-Virus (1x10
8
 particles/tumor + 1x10
8
 vp/tumor). (B) Representative 
images that indicate the intensity of photon emission in 7 organs explanted from NFKB-luc2 i.v. treated with EV-DiD-
Virus. (C) Quantification of fluorescence emission was assessed from liver and tumor tissue  using the Living Image 
Software (PerkinElmer) and CCD-camera (IVIS Lumina II Quantitative Fluorescent and Bioluminescent Imaging; 
PerkinElmer, Waltham, MA, USA).  
 
 
.  
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Supplementary Figure 6. DiD alone does not show positive fluorescent signal in the tumor site. (B) Representative 
images that indicate the intensity of photon emission in 7 organs explanted from NFKB-luc2 iv treated with DiD. 
 
 
Supplementary Figure 7. Ex vivo fluorescence in murine body areas. Quantification of fluorescence 
emission was assessed using the Living Image Software (PerkinElmer) and CCD-camera (IVIS Lumina II 
Quantitative Fluorescent and Bioluminescent Imaging; PerkinElmer, Waltham, MA, USA).  
 
 
Peritumoral infiltration of TILs induced by oncolytic viruses is unaffected by EVs 
 
Next, we analyzed whether the type of inflammatory response recruited by the OVs [62], could be 
influenced by the delivery of the virus via EVs. To this aim, the immune cells infiltrating the resected 
tumors were analyzed by flow cytometry at sacrifice, 24h post-treatment; the amount of murine 
CD45+ (pan-leucocyte marker) was initially quantified (Figure 6B) and then the proportion of 
murine CD3+ T-cells among CD45+ leukocytes was calculated: the data indicated that there was a 
trend to increase of the CD3+ cell type in the Virus, EV-Virus and EV-Virus-PTX groups (Figure 
6C). Similar data were obtained for the subpopulation of CD4+ and CD8+ T-cells displaying a non-
significant increased infiltration in the same treatment groups (Figure 6DE). Therefore, we concluded 
that OVs alone or EV encapsulated with other drugs might enhance immunogenicity; although the 
significance of this observation has to be firmly established in future studies, we could conclude that 
the encapsulation of virus into EVs was not interfering with the observed immunogenic response. 
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Figure 6. Biodistribution of virus and immune cell infiltration. (A) Adenoviral copies towards E4 gene were 
measured by qPCR from euthanized mice's organs (tumor, liver, serum and brain) at the end of the treatment. Error bars 
mean+/- SD *p<0.05, **p<0.01, ***p<0.001.  (B-E) % of murine CD45+, CD3+, CD4+, CD8+ T-cells was quantified 
from resected tumors by flow cytometer. Results are presented as mean +/- SD. N=5/group.  One-way ANOVA analysis 
did not evidence statistical differences between the tested groups. 
 
 
 
DISCUSSION  
 
     The use of EVs as delivery system of OVs [39,63] or anti-neoplastic drugs [37,64] is a promising 
therapeutic strategy for primary and metastatic cancers. Nevertheless, the EVs biodistribution profile 
[65] and the potential side-effects associated with the systemic administration of OVs encapsulated in 
EVs are still poorly characterized. We have previously developed a strategy to encapsulate in EVs 
anti-cancer agents, including OVs and PTX together, showing, for the first time, that these 
formulations can be administered systemically: we reported a selective cancer cell tropism along with  
inhibition of cancer cell growth in nude mice, thus exploiting their potential use  of these novel 
therapeutic concept also for the treatment of metastatic cancers [39]. In the current study, by using an 
immunocompetent reporter mouse model (NFkB-luc2), we aimed at assessing the effects of the 
intravenous delivery of these EVs formulations on the systemic and tumor-associated inflammation.  
In fact, although extensive studies have been conducted to demonstrate their potential as drug 
delivery vessels [34,38,66–69], still little is known about the possible immunogenic or potential toxic 
effects of EVs [70]. This is especially important given that some of the EV cargo may carry toxic 
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constituents or may instigate inflammatory responses [70–72]. Our in vivo imaging evidence on EVs 
biodistribution clearly show a targeted delivery of the particles selectively to the tumor tissues: we 
found that the systemic effects of PTX resulting in a diffuse inflammatory reaction, were efficiently 
reduced by encapsulating the drug inside EVs (Figure 4AF). This is a promising result showing that 
the potential toxic and inflammatory effects of PTX on the whole body can be prevented by the 
ability of the nanoparticles to specifically target the tumor tissue. In addition, it has been previously 
reported that EVs may release mediators of the immune response, such as interleukin (IL)-1β [73–
75], IL-18 [76], IL-8 [77], lipid mediators [78,79], matrix metalloproteinases [80] and miRNAs such 
as let-7, miRNA-21, and miR-29a [81,82], nevertheless, our in vivo imaging data clearly indicate that 
no systemic reaction could be detected other than the tumor associated inflammation.   
It is well-known that tumor-associated inflammation may have positive or negative effects depending 
on the type of the produced immune response [83]: while cytotoxic response is essential for tumor 
cell removal from the body [84], the response associated with tissue repair may promote invasion and 
angiogenesis through the secretion of specific growth factors and cytokines [85,86]. The ability of 
oncolytic adenovirus ONCOS-102 to elicit immune-activation has been already reported in phase I 
clinical study, showing short-term increase in systemic pro-inflammatory cytokines, a prominent 
infiltration of TILs in tumors post-treatment (11 out of 12 patients) and systemic induction of tumor-
specific CD8+ T cells (2 patients) [26]. Hence, oncolytic therapy does not only kill cancer cells by 
direct lysis, but also generate antitumor immune responses, long‐ lasting cancer control and tumor 
reduction [87]. We found that the systemic administration of OVs encapsulated in EVs enhances 
immunogenicity of cancer cell death in vitro and resulted in infiltration of CD3+, CD4+ and CD8+ 
T-cells into tumors. Moreover, we demonstrated that EV formulations does not negatively influence 
the cytotoxic tumor-associated response induced by the treatment with OVs (in terms of 
inflammatory cell infiltrates). Taken together, these results may suggest an enhanced cytotoxic 
immune effect at the tumor site induced by OVs when encapsulated in EVs; certainly, the impact of 
these effects have to be further investigated in long-lasting experiments focusing on anti-tumor 
efficacy, but this was not the primary aim of this work. In addition, encapsulating OVs inside the 
EVs may also have the added value to allow the virus to escape from immune-surveillance, making it 
less detectable and thus likely more effective.   
Despite these potential advantages in using EVs as drug delivery tools, there are still some challenges 
to overcome for its clinical application. Currently there are no universal protocols for EV production, 
as carriers for drug delivery, thus a standardized protocol should be developed in the near future [88]. 
Indeed, the low production yield  of EVs together with their short half-life, after i.v. administration, is 
a big hurdle that need to be beaten [66,88–90] before their application for clinical purposes.  It has 
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been reported that some cancer cell-derived EVs have a nano-filamentous network, which facilitates 
interaction with the cell membrane and increases the EV-uptake [67]. These characteristics could 
possibly be considered for improvements in the design of efficient EV-based drug carriers to be used 
in cancer therapy [91]. Future studies should take advantage of the EVs pseudo-typing to improve 
specificity and to drive their tropism towards specific cancers. For instance, EVs expressing Integrin 
alpha V beta 5 (ITGavb5), bind specifically to Kupffer cells, mediating liver tropism, while other 
integrins ITGa6b4  and ITGa6b1 on EVs bind to lung-resident fibroblasts and epithelial cells, leading 
to lung tropism [92]. Therefore, by specific modifications of ITGavb5, the tropism of EVs could be 
changed. The pseudotyped EVs combined with the last generation OVs carrying genetic 
modifications for a cancer-cell restricted replication, may further reduce the potential off-target 
effects linked to the systemic delivery. The final goal is to exploit the OVs specific oncolytic and 
immunomodulatory activities and combine them with anti-cancer properties of currently available 
drugs for an EV-driven, highly effective treatment.  
 
 
CONCLUSION 
In this study, we supported EVs as a tool for systemic delivery of anticancer agents alone or in a 
combination therapy. We demonstrated the ability of EVs to selectively deliver anti-neoplastic agents 
to the tumor tissue, thus, potentially reducing the systemic effect of chemotherapy. Moreover, we 
showed that encapsulation into EVs does not change the ability of OVs to stimulate a tumor-
associated inflammatory response in terms of NFκB stimulation, enhanced immunogenicity and 
infiltration of CD3+, CD4+ and CD8+ T-cells. Altogether, our experiments strongly support the 
systemic administration of anticancer agent combinations encapsulated into EVs as a novel, safe and 
efficacious therapeutic strategy aimed at treating primary and metastatic cancers.  
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